Novasep has announced the acquisition of Henogen, a contract manufacturing organization offering bioprocess development and manufacturing services from the cell bank to the supply of clinical products. The move adds a range of upstream processing capabilities and services to Novasep?s current downstream offerings.
Novasep has announced the acquisition of Henogen, a contract manufacturing organization offering bioprocess development and manufacturing services from the cell bank to the supply of clinical products. The move adds a range of upstream processing capabilities and services to Novasep’s current downstream offerings.
The company now offers a combination of solutions for biopharmaceutical manufacturing. These include insourcing solutions, such as chromatography and membrane filtration technologies and complete downstream processing from lab to industrial scale, as well as outsourcing solutions including contract biomanufacturing services from the cell bank to the vial.
"Novasep is making another strategic step forward with the acquisition of Henogen," said Dr Roger-Marc Nicoud, president and CEO of the company. "The two companies have an excellent range of complementary capabilities and we look forward to offering our customers an even wider range of manufacturing services."
For more information visit the company’s website at www.novasep.com
Targeted Blood Lipidomics of Colorectal Cancer: An HTC-18 Interview with Jef Focant
July 26th 2024At HTC-18 in Leuven, Executive Editor of LCGC International, Alasdair Matheson, spoke to Jef Focant from the University of Liege about his talk entitled, “Targeted Blood Lipidomics of Colorectal Cancer."
Carol Robinson Awarded 2024 Lifetime Achievement European Inventor Award
July 24th 2024Carol Robinson of the University of Oxford has received the European Inventor Award 2024 for Lifetime Achievement from the European Patent Office for her work bringing mass spectrometry to structural biology.